Modeling the Impact of Monthly Titration of Once-Weekly Insulin Icodec in Insulin-Naive Type 2 Diabetes: Analysis Based on ONWARDS 1 and 3

To explore whether monthly titration of once-weekly insulin icodec (icodec) could provide a feasible alternative to the weekly titration utilized in ONWARDS 1 and 3 for insulin-naive individuals with type 2 diabetes (T2D), supporting less-frequent dose adjustments tailored to individual needs. A validated pharmacokinetic/pharmacodynamic icodec model was adapted using pooled ONWARDS 1 and 3 data to simulate weekly and two different monthly titration scenarios, applying the same initiation dose and self-measured blood glucose (SMBG) target used in the trials. Scenarios 1 and 2 used ± 20 U and ± 50 U adjustments, respectively, informed by the last three fasting SMBG values. Simulations of fasting SMBG, glycated hemoglobin (HbA 1c ), icodec dose, and clinically significant (level 2) hypoglycemia were performed over 78 weeks. At week 78, model-predicted mean (95% range) HbA 1c was 7.3% (6.2–9.2%) for scenario 1 and 7.2% (6.0–8.9%) for scenario 2, versus 6.9% (5.9–8.4%) for the weekly titration reference. Model-predicted mean (95% range) prebreakfast SMBG was 7.3 mmol/L (6.0–9.8 mmol/L) and 7.1 mmol/L (5.6–9.3 mmol/L) versus 6.6 mmol/L (5.3–8.3 mmol/L), respectively. Predicted cumulative rates of clinically significant (level 2) hypoglycemia were 0.081 (scenario 1) and 0.15 (scenario 2) events per patient-year of exposure (PYE), both numerically lower than the already low rate predicted for the weekly titration (0.34 events per PYE). These lower predicted rates occurred alongside lower predicted icodec doses. Our findings support the feasibility of monthly titration of icodec as an alternative to weekly titration for individuals with T2D who require or prefer less-frequent dose adjustments. Prospective clinical evaluation is needed to confirm these model-based findings. ClinicalTrials.gov identifiers: NCT04460885 (ONWARDS 1), NCT04795531 (ONWARDS 3).

Authors

Institutions

Publication Details

Journal
Diabetes Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s13300-026-01928-7
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modeling the Impact of Monthly Titration of Once-Weekly Insulin Icodec in Insulin-Naive Type 2 Diabetes: Analysis Based on ONWARDS 1 and 3

Niels Rode Kristensen, Peter Lin, Cyrus V Desouza, Stinne Byrholdt Søgaard et al.
Diabetes Therapy
Diabetes Management and Research
article

Modeling the Impact of Monthly Titration of Once-Weekly Insulin Icodec in Insulin-Naive Type 2 Diabetes: Analysis Based on ONWARDS 1 and 3

Niels Rode Kristensen, Peter Lin, Cyrus V Desouza, Stinne Byrholdt Søgaard, Andreas Liebl, Ariel Fu
article en

Abstract

To explore whether monthly titration of once-weekly insulin icodec (icodec) could provide a feasible alternative to the weekly titration utilized in ONWARDS 1 and 3 for insulin-naive individuals with type 2 diabetes (T2D), supporting less-frequent dose adjustments tailored to individual needs. A validated pharmacokinetic/pharmacodynamic icodec model was adapted using pooled ONWARDS 1 and 3 data to simulate weekly and two different monthly titration scenarios, applying the same initiation dose and self-measured blood glucose (SMBG) target used in the trials. Scenarios 1 and 2 used ± 20 U and ± 50 U adjustments, respectively, informed by the last three fasting SMBG values. Simulations of fasting SMBG, glycated hemoglobin (HbA 1c ), icodec dose, and clinically significant (level 2) hypoglycemia were performed over 78 weeks. At week 78, model-predicted mean (95% range) HbA 1c was 7.3% (6.2–9.2%) for scenario 1 and 7.2% (6.0–8.9%) for scenario 2, versus 6.9% (5.9–8.4%) for the weekly titration reference. Model-predicted mean (95% range) prebreakfast SMBG was 7.3 mmol/L (6.0–9.8 mmol/L) and 7.1 mmol/L (5.6–9.3 mmol/L) versus 6.6 mmol/L (5.3–8.3 mmol/L), respectively. Predicted cumulative rates of clinically significant (level 2) hypoglycemia were 0.081 (scenario 1) and 0.15 (scenario 2) events per patient-year of exposure (PYE), both numerically lower than the already low rate predicted for the weekly titration (0.34 events per PYE). These lower predicted rates occurred alongside lower predicted icodec doses. Our findings support the feasibility of monthly titration of icodec as an alternative to weekly titration for individuals with T2D who require or prefer less-frequent dose adjustments. Prospective clinical evaluation is needed to confirm these model-based findings. ClinicalTrials.gov identifiers: NCT04460885 (ONWARDS 1), NCT04795531 (ONWARDS 3).

Diabetes Therapy
Novo Nordisk (Denmark) (DK), Canadian Heart Research Centre (CA), University of Nebraska Medical Center (US)
Good health and well-being
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon